威高股份(01066)发布公告，于2026年2月2日该公司斥资109.7万港元回购22万股，回购价格为每股4.98- 5.00港元。 ...

《2025年度业绩预告》 最新公告列表 截至2026年2月2日收盘，天益医疗（301097）报收于57.11元，较前一交易日下跌4.71%，最新总市值为 33.66亿元。该股当日开盘57.8元，最高59.2元，最低55.13元，成交额达1.44亿元，换手率为8.74%。 近日，宁波天益医疗器械股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润 为-1,800.00万元至-1,100.00万元，较上年同期下降1,378.49%至2,319.35%。扣除非经常性损益后的净利 润预计为-1,300.00万元至-800.00万元。业绩下滑主要由于计提行政处罚金额、联营企业CRRT业务整合 导致投资损失、美元汇率波动引发汇兑损失增加以及存货跌价准备计提增加所致。该预告为公司财务部 门初步测算结果，未经会计师事务所审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

2026年1月30日， Siemens Healthineers 西门子医疗 宣布，其位于爱尔兰都柏林北部 Swords 的全新免 疫分析仪器研发卓越中心（Centre of Excellence for Immunoassay Instrument R&D）正式启用。 该项目迄今已累计投入 1200 万美元 （约合人民币8300万） ，公司同时确认，后续仍将持续追加投资， 用于研发能力扩展及可持续发展相关建设。 从时间轴看，这一研发中心的落成，标志着西门子医疗 自 2023 年启动的一项多年投资计划完成收官 ，也 再次强化了其在爱尔兰本土的研发与制造布局。 # 从"制造基地"走向"研发—生产一体化" Swords 并不是一个全新的选址。 西门子医疗在爱尔兰已有 超过 100 年 的运营历史，该区域长期承担着诊断设备的制造职能。 此次不同之处在于—— 研发能力被正式引入并与既有制造体系"并轨" 。 根据公司披露，新研发中心选址于新购置的厂房内，与现有生产设施直接相邻，目标是实现 免疫分析与临 床化学仪器在设计、工程验证到规模化生产之间的快速衔接 。 西门子医疗诊断业务全球硬件工程研发负责人 Patrick G ...

Core Viewpoint - The article discusses the recent advancements in the use of PEEK (Polyether Ether Ketone) materials in neurosurgery, highlighting its endorsement in the latest expert consensus and the impact of policy changes on market accessibility [3][6][8]. Group 1: Expert Consensus and Material Endorsement - The "Expert Consensus on Cranioplasty" published in August 2025 recommends PEEK as a primary material for cranioplasty, marking a significant update in clinical application standards [3][6]. - PEEK's mechanical properties closely resemble natural bone, providing excellent stability and biocompatibility, which facilitates postoperative assessments [7]. Group 2: Market Dynamics and Policy Impact - The application history of PEEK in neurosurgery reflects the development trajectory of China's high-end medical materials market, with its initial use in aerospace before entering the medical implant sector [9]. - Despite its superior performance, PEEK faced market penetration challenges due to its high cost compared to traditional titanium mesh, limiting its accessibility to a select group of patients [9]. - Recent international procurement and healthcare reform policies have begun to lower the end-user prices of PEEK products, improving clinical accessibility and allowing more patients to benefit from high-performance materials [9]. Group 3: Innovative Solutions and Product Development - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. has launched the SAILU® craniofacial repair system, which integrates PEEK materials and a comprehensive service system based on a decade of customization experience [10]. - The SAILU® product design addresses clinical needs with features that enhance surgical efficiency and adaptability, particularly for pediatric patients [12]. - Maipu has expanded its product line to include the Luchang® hydrophilic coating cranial drainage kit, which has been included in the provincial alliance procurement directory, showcasing ongoing innovation in neurosurgical products [16][18]. Group 4: Future Trends and Market Transformation - The endorsement of PEEK materials in the new expert consensus and the steady progress of provincial alliance procurement are driving a shift towards a performance-first, value-oriented model in the high-value consumables market for neurosurgery [18]. - The collaboration between advancements in material science and healthcare policies is systematically improving treatment pathways and outcomes for patients with cranial defects [18].

Core Viewpoint - The article discusses the recent approval of 10 innovative medical devices by the National Medical Products Administration (NMPA) in China, highlighting the advancements in the medical technology sector and the companies involved in these innovations [1]. Group 1: Innovative Medical Devices - The first product is a software for assessing chronic obstructive pulmonary disease, developed by Bojiang Life Sciences (Shanghai) Co., Ltd., which focuses on digital biomarkers and therapies for chronic disease management [2]. - The second product is an ultrasound therapy device from Shenzhen Tengfu Medical Technology Co., Ltd., which specializes in interventional devices for pulmonary embolism treatment [3]. - The third product is a transcatheter artificial tricuspid valve developed by Edwards Lifesciences, a leading company in structural heart disease devices [4][5]. - The fourth product is an ultrasound thrombolysis catheter and stent system from Shanghai Tengfu Medical Technology Co., Ltd., aimed at providing safer treatment options for venous thromboembolism [9][11]. - The fifth product is a radiation therapy planning software from Guoke Ion Medical Technology Co., Ltd., which focuses on the industrialization of medical heavy ion technology [12]. - The sixth product is an implantable cardioverter-defibrillator from Chuangling Heart Rhythm Management Medical Device (Shanghai) Co., Ltd., which aims to provide high-quality heart rhythm management products [13]. - The seventh product is a peripheral balloon-expandable stent system from Zhejiang Guichuang Medical Technology Co., Ltd., which specializes in high-end vascular interventional devices [14]. - The eighth product is a thoracoabdominal endoscopic surgical system from Intuitive Surgical, a global leader in robotic-assisted minimally invasive surgery [15][16]. - The ninth product is a coronary sinus balloon counterpulsation system from Shanghai Micron Melody Medical Technology Co., Ltd., which focuses on coronary intervention devices [17].

Core Viewpoint - The company is facing unusual losses in the fourth quarter and has been questioned by investors regarding its financial performance and future disclosures [2] Group 1: Financial Performance - The company has received inquiries about the unusual losses reported in the fourth quarter [2] - The company will disclose its annual report for 2025 on March 25, 2026, which will include detailed performance data [2] Group 2: Compliance and Information Disclosure - The company emphasizes its commitment to strict adherence to information disclosure principles to ensure fair access to information for investors [2]

Core Viewpoint - Gongdong Medical (605369.SH) has announced that its testing center meets the requirements of ISO/IEC 17025:2017 and has obtained the CNAS laboratory accreditation certificate, indicating a significant enhancement in its management and technical capabilities [1] Group 1 - The acquisition of the CNAS laboratory accreditation certificate signifies national and international recognition of the company's testing center's management level and technical ability [1] - This certification will help reduce the market entry barriers and external testing costs for the company's products in both domestic and international markets [1] - The recognition supports product quality control, performance validation, and research and development innovation, thereby enhancing the company's overall competitiveness [1]

Market Overview - The medical device sector experienced a decline of 1.98% on February 2, with Hai Li Biological leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Top Performers - Mai Pu Medical (301033) saw a closing price of 73.70, with an increase of 8.35% and a trading volume of 31,100 shares, totaling 223 million yuan [1] - Nanwei Co., Ltd. (603880) closed at 6.63, up 5.41%, with a trading volume of 191,200 shares, amounting to 126 million yuan [1] - Gongdong Medical (605369) closed at 19.46, up 2.91%, with a trading volume of 44,800 shares, totaling 86.97 million yuan [1] Underperformers - Hai Li Biological (603718) closed at 5.84, down 10.02%, with a trading volume of 84,500 shares, totaling 49.32 million yuan [2] - Yuanmei Medical (002950) closed at 10.46, down 9.52%, with a trading volume of 255,000 shares, amounting to 269 million yuan [2] - Yikang Technology (688301) closed at 111.34, down 5.92%, with a trading volume of 44,200 shares, totaling 503 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 533 million yuan from institutional investors, while retail investors experienced a net inflow of 174 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Sino Medical (688108) had a net inflow of 46.28 million yuan from institutional investors, while retail investors saw a net outflow of 58.30 million yuan [3] - Mai Pu Medical (301033) experienced a net inflow of 29.68 million yuan from institutional investors, with a net outflow of 34.84 million yuan from retail investors [3] - Gongdong Medical (605369) had a net inflow of 13.18 million yuan from institutional investors, while retail investors faced a net outflow of 9.00 million yuan [3]

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has received approval for its initial public offering and is set to list on the Sci-Tech Innovation Board, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] Group 1: Company Overview - Beixin Life is a national high-tech enterprise specializing in the research, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [1] - The company is the first in China to have a product combination of intravascular functional FFR and imaging IVUS, establishing a high-performance and high-barrier system for active interventional medical devices [2] Group 2: Product Development and Innovation - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under research, covering five major categories including IVUS systems and FFR systems [2] - The core product, the IVUS system, is the first domestically developed 60MHz high-definition and high-speed IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [2] Group 3: Financial Performance - In the first half of 2025, sales revenue from FFR pressure microcatheters and IVUS catheters accounted for 82.16% of total sales, indicating the continued dominance of core products in the market [3] - Beixin Life achieved a revenue of 259 million yuan and a net profit of 45.51 million yuan in the first half of 2025, marking its first profitable period [3] Group 4: Intellectual Property and Recognition - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [4] - The company has been recognized as a "National Specialized and New 'Little Giant' Enterprise" and has received various awards for its core products, highlighting its technological capabilities and market recognition [4] Group 5: Future Outlook - The upcoming IPO is expected to optimize the company's capital structure, reduce debt risk, and enhance its research and development capabilities [6] - Beixin Life aims to continue advancing its product development and expand the application range of existing products, solidifying its comprehensive platform for cardiovascular disease diagnosis and treatment [6]

（文章来源：证券日报） 证券日报网讯 2月2日，凯普生物在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东总 户数为28673户。 ...